Published in Biochim Biophys Acta on July 10, 2009
Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol (2015) 2.08
PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett (2012) 1.77
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release (2009) 1.76
Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release (2011) 1.72
Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release (2010) 1.64
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64
Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond) (2010) 1.51
Recent advances in nonviral vectors for gene delivery. Acc Chem Res (2011) 1.48
Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res (2010) 1.38
Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials (2011) 1.24
PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine (2012) 1.01
Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials (2013) 0.99
Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer. Mol Pharm (2014) 0.94
The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles. Biomaterials (2012) 0.94
Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J Control Release (2014) 0.92
Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation. Int J Nanomedicine (2010) 0.92
Non-degradative intracellular trafficking of highly compacted polymeric DNA nanoparticles. J Control Release (2011) 0.91
Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors. J Pharm Innov (2014) 0.89
Novel molecular and nanosensors for in vivo sensing. Theranostics (2013) 0.89
Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm (2012) 0.89
Gold nanorod--siRNA induces efficient in vivo gene silencing in the rat hippocampus. Nanomedicine (Lond) (2011) 0.88
High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano (2016) 0.87
Delivery of intracellular-acting biologics in pro-apoptotic therapies. Curr Pharm Des (2011) 0.87
Nanoparticle delivery of a peptide targeting EGFR signaling. J Control Release (2011) 0.87
Recent advances in protein and Peptide drug delivery: a special emphasis on polymeric nanoparticles. Protein Pept Lett (2014) 0.86
Nanoparticles containing insoluble drug for cancer therapy. Biotechnol Adv (2013) 0.86
Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.84
Nanoliposomes for encapsulation and delivery of the potential antitumoral methyl 6-methoxy-3-(4-methoxyphenyl)-1H-indole-2-carboxylate. Nanoscale Res Lett (2011) 0.83
Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale (2014) 0.83
Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv (2012) 0.83
The impact of PEGylation patterns on the in vivo biodistribution of mixed shell micelles. Int J Nanomedicine (2013) 0.81
Targeted delivery of EV peptide to tumor cell cytoplasm using lipid coated calcium carbonate nanoparticles. Cancer Lett (2012) 0.81
Lipid-based vectors for siRNA delivery. J Drug Target (2012) 0.81
Nanoparticle ligand presentation for targeting solid tumors. AAPS PharmSciTech (2014) 0.80
Assembly of bio-nanoparticles for double controlled drug release. PLoS One (2013) 0.80
Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities. Biotechnol Adv (2013) 0.80
Detection of Phosphatidylcholine-Coated Gold Nanoparticles in Orthotopic Pancreatic Adenocarcinoma using Hyperspectral Imaging. PLoS One (2015) 0.80
Effect of surface properties on liposomal siRNA delivery. Biomaterials (2015) 0.80
Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery. J Histochem Cytochem (2013) 0.79
Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery. Pharm Res (2015) 0.79
Development of a novel lipophilic, magnetic nanoparticle for in vivo drug delivery. Pharmaceutics (2013) 0.79
Delivery of therapeutic radioisotopes using nanoparticle platforms: potential benefit in systemic radiation therapy. Nanotechnol Sci Appl (2010) 0.78
The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model. J Exp Clin Cancer Res (2014) 0.78
pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells. Int J Nanomedicine (2015) 0.78
Physiologically based pharmacokinetic modeling of zinc oxide nanoparticles and zinc nitrate in mice. Int J Nanomedicine (2015) 0.77
Multistage Delivery Technologies: Multifunctional, Interdisciplinary Approaches to Nanomedicine. Mol Ther (2016) 0.77
Highly compacted pH-responsive DNA nanoparticles mediate transgene silencing in experimental glioma. J Mater Chem B Mater Biol Med (2014) 0.77
Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier. Mol Pharm (2014) 0.77
Recent progress in the development of polysaccharide conjugates of docetaxel and paclitaxel. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.77
Durable expression of minicircle DNA-liposome-delivered androgen receptor cDNA in mice with hepatocellular carcinoma. Biomed Res Int (2014) 0.77
Characterization of the host-guest complex of a curcumin analog with β-cyclodextrin and β-cyclodextrin-gemini surfactant and evaluation of its anticancer activity. Int J Nanomedicine (2015) 0.77
Amorphous calcium phosphate nanoparticles could function as a novel cancer therapeutic agent by employing a suitable targeted drug delivery platform. Nanoscale Res Lett (2013) 0.77
Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers. Int J Nanomedicine (2011) 0.77
Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition. Mol Ther (2017) 0.77
Topical enzyme-replacement therapy restores transglutaminase 1 activity and corrects architecture of transglutaminase-1-deficient skin grafts. Am J Hum Genet (2013) 0.76
Lipid nanoparticles for gene delivery. Adv Genet (2014) 0.76
Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate. J Control Release (2013) 0.76
An interdisciplinary computational/experimental approach to evaluate drug-loaded gold nanoparticle tumor cytotoxicity. Nanomedicine (Lond) (2016) 0.76
Evaluation of uptake and distribution of gold nanoparticles in solid tumors. Eur Phys J Plus (2015) 0.76
A detachable coating of cholesterol-anchored PEG improves tumor targeting of cell-penetrating peptide-modified liposomes. Acta Pharm Sin B (2014) 0.76
Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma. Int J Nanomedicine (2015) 0.75
Composite nanoparticles for gene delivery. Adv Genet (2014) 0.75
Morphological Analysis of Reticuloendothelial System in Capuchin Monkeys (Sapajus spp.) after Meso-2,3-Dimercaptosuccinic Acid (DMSA) Coated Magnetic Nanoparticles Administration. PLoS One (2015) 0.75
Development of Sialic Acid-coated Nanoparticles for Targeting Cancer and Efficient Evasion of the Immune System. Theranostics (2017) 0.75
Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems. Kona (2016) 0.75
Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer. Nanomaterials (Basel) (2016) 0.75
Homing in on an intracellular target for delivery of loaded nanoparticles functionalized with a histone deacetylase inhibitor. Oncotarget (2017) 0.75
Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery. ACS Appl Mater Interfaces (2016) 0.75
Cancer-Associated, Stimuli-Driven, Turn on Theranostics for Multimodality Imaging and Therapy. Adv Mater (2017) 0.75
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm (2005) 7.53
Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev (2004) 5.31
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett (1990) 5.14
Sterically stabilized liposomes. Biochim Biophys Acta (1992) 3.10
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol (2002) 2.62
Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys J (1995) 2.35
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm (2006) 2.28
Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res (1999) 2.00
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release (2007) 1.68
Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta (2007) 1.56
In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther (1997) 1.51
Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett (1996) 1.46
Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids (2005) 1.34
Liposome opsonization. J Liposome Res (2005) 1.26
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm (2009) 1.21
Effect of grafted polyethylene glycol (PEG) on the size, encapsulation efficiency and permeability of vesicles. Biochim Biophys Acta (2000) 1.06
LPD nanoparticles--novel nonviral vector for efficient gene delivery. Methods Mol Med (2002) 1.03
Effects of PEG-lipids on permeability of phosphatidylcholine/cholesterol liposomes in buffer and in human serum. Chem Phys Lipids (1998) 0.97
Lipid-protamine-DNA-mediated antigen delivery. Curr Drug Deliv (2005) 0.90
Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm (2008) 3.92
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer (2004) 2.31
Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30
Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm (2006) 2.28
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release (2008) 1.95
Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol (2010) 1.81
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release (2009) 1.76
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release (2011) 1.72
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release (2007) 1.68
Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release (2010) 1.64
In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 1.59
Non-viral is superior to viral gene delivery. J Control Release (2007) 1.54
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Recent advances in nonviral vectors for gene delivery. Acc Chem Res (2011) 1.48
Surface-modified LPD nanoparticles for tumor targeting. Ann N Y Acad Sci (2006) 1.46
Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res (2010) 1.38
Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on transfection efficiency. Biomaterials (2006) 1.30
Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem (2010) 1.28
Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc (2010) 1.27
Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol (2007) 1.24
A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano (2013) 1.22
Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine (2012) 1.21
Development of non-viral vectors for systemic gene delivery. J Control Release (2002) 1.21
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm (2009) 1.21
Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther (2005) 1.19
Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther (2010) 1.17
Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther (2011) 1.15
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm (2005) 1.11
Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci (2010) 1.10
Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev (2005) 1.10
A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother (2007) 1.08
The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm (2011) 1.08
Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release (2013) 1.08
HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J Control Release (2004) 1.08
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther (2012) 1.07
Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano (2013) 1.07
LPD nanoparticles--novel nonviral vector for efficient gene delivery. Methods Mol Med (2002) 1.03
Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J Control Release (2008) 1.03
Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm (2010) 1.02
Mechanistic studies of sequential injection of cationic liposome and plasmid DNA. Mol Ther (2005) 1.01
Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother (2005) 1.01
Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method? Pharm Res (2012) 1.00
Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm (2012) 1.00
Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials (2013) 0.99
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther (2013) 0.98
Electroporatic delivery of TGF-beta1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. J Invest Dermatol (2004) 0.98
Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano (2014) 0.97
Recent advances in intravesical drug/gene delivery. Mol Pharm (2006) 0.97
Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol (2006) 0.96
The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles. Biomaterials (2012) 0.94
Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol (2004) 0.93
Noninvasive gene delivery to the liver by mechanical massage. Hepatology (2002) 0.92
Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Mol Ther (2005) 0.92
A syringe electrode device for simultaneous injection of DNA and electrotransfer. Mol Ther (2002) 0.92
Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res (2004) 0.92
Controlled gene delivery system based on thermosensitive biodegradable hydrogel. Pharm Res (2003) 0.91
Non-immunostimulatory nonviral vectors. FASEB J (2004) 0.91
Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano (2014) 0.91
Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat. Urology (2003) 0.91
Lipid-protamine-DNA-mediated antigen delivery. Curr Drug Deliv (2005) 0.90
Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials (2013) 0.90
Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs (2008) 0.90
Activity of different phospholipids in attenuating hyperactivity in bladder irritation. BJU Int (2007) 0.90
Enhanced cutaneous gene delivery following intradermal injection of naked DNA in a high ionic strength solution. Mol Ther (2002) 0.89
Recent advances in non-viral gene delivery. Adv Genet (2005) 0.89
Non-viral vector as vaccine carrier. Adv Genet (2005) 0.88
Thermosensitive hydrogel as a Tgf-beta1 gene delivery vehicle enhances diabetic wound healing. Pharm Res (2003) 0.88
Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol Pharm (2008) 0.88
Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. Urology (2003) 0.87
Mechanism of in vivo DNA transport into cells by electroporation: electrophoresis across the plasma membrane may not be involved. J Gene Med (2006) 0.87
Several serum proteins significantly decrease inflammatory response to lipid-based non-viral vectors. Mol Ther (2007) 0.87
Nanoparticle delivery of a peptide targeting EGFR signaling. J Control Release (2011) 0.87
Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv (2008) 0.86
Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. Cancer Immunol Immunother (2011) 0.86
Mechanism of naked DNA clearance after intravenous injection. J Gene Med (2007) 0.86
Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm (2010) 0.85
Recent Advances in Non-viral Gene Delivery. Adv Genet (2005) 0.85
Mechanism of liver gene transfer by mechanical massage. Mol Ther (2004) 0.84
Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J Biol Chem (2012) 0.84
Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm Res (2004) 0.84
Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates. Mol Pharm (2006) 0.84
Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum Gene Ther (2002) 0.84
How does the cell overcome LCP nanoparticle-induced calcium toxicity? Mol Pharm (2013) 0.83
Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res (2002) 0.83
Cancer immunotherapy and nanomedicine. Pharm Res (2010) 0.83
Gene transfer to subdermal tissues via a new gene gun design. Hum Gene Ther (2003) 0.83
Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv (2012) 0.83
Novel nonviral vectors target cellular signaling pathways: regulated gene expression and reduced toxicity. J Pharmacol Exp Ther (2007) 0.82
Smart polymeric nanoparticles for cancer gene delivery. Mol Pharm (2015) 0.82
Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. J Control Release (2013) 0.81
Targeted delivery of RNAi therapeutics for cancer therapy. Nanomedicine (Lond) (2010) 0.81
Cationic liposome-protamine-DNA complexes for gene delivery. Methods Enzymol (2003) 0.81
Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model. Mol Pharm (2011) 0.81
Lipid-based vectors for siRNA delivery. J Drug Target (2012) 0.81
The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome. Int J Pharm (2008) 0.81